Integra LifeSciences Holdings Corp reported its 2025 second quarter financial results, with a stock price of $12.37 and a market capitalization of $961.3 million, amidst a growing biosurgery market with significant growth opportunities.

Integra LifeSciences Holdings Corp’s stock price plummeted 25% in Q1 2025, driven by a widened loss, earnings miss, and strategic missteps, leaving its future prospects uncertain.

Integra LifeSciences Holdings Corp’s stock plummeted 25% after a widened first-quarter loss, but the company projects a potential rebound with a revenue range of $390-400 million in the second quarter.

Integra LifeSciences Holdings Corp has released its Q1 2025 financial results, showing a significant decrease in stock price and a negative price-to-earnings ratio, amidst a growing burn care market.